{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-274327","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.381709+00:00","generated_at":"2026-05-29T05:19:31.238958+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"NewAmsterdam Pharma terminates $150M ATM equity offering program","bullets":["Company delivered notice to Cowen and TD Cowen to suspend and terminate ATM prospectus supplement dated August 9, 2024.","Program allowed for sale of up to $150M of ordinary shares.","No sales will be made under Sales Agreement until new prospectus or registration statement is filed.","Sales Agreement remains in full force and effect other than the terminated ATM prospectus."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-274327","json":"https://secwatch.observer/filing/0001193125-24-274327.json","markdown":"https://secwatch.observer/filing/0001193125-24-274327.md","text":"https://secwatch.observer/filing/0001193125-24-274327.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524274327/0001193125-24-274327-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524274327/d913585d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:19:31.238958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}